Literature DB >> 6757774

Renin-angiotensin-aldosterone system in mild diabetic nephropathy.

K Tomita, O Matsuda, T Ideura, T Shiigai, J Takeuchi.   

Abstract

The mechanism of lowered renin-aldosterone system was investigated in 17 patients with diabetic nephropathy (serum Cr less than 3 mg/100 ml) with concomitant control of the blood sugar level. The response of plasma renin activity (PRA) to upright stimulation was lower in the low renin group (group I) than in the normal to high renin group (group II) and in the control group. The PRA response to theophylline was delayed in group I. The percentage of the luminal area of the arteriole in the biopsy specimens was larger in group I and the control group than in group II. Plasma aldosterone concentration (PAC) was not increased by angiotensin II in group I. Low PRA in diabetic nephropathy with slightly to moderately impaired renal function may not be due to hyaline destruction of the arteriolar walls, but to other factors such as sympathetic nervous dysfunction. The adrenal responses of PAC to angiotensin II may also be impaired.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6757774     DOI: 10.1159/000182682

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Renal vessel changes in diabetic KK-mice.

Authors:  H P Volkmann; H Wehner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

2.  Plasma renin activity and urinary kallikrein excretion in response to intravenous furosemide in diabetic patients.

Authors:  S B Lall; S Kunchaparty; H H Siddiqui; J S Bajaj
Journal:  Acta Diabetol Lat       Date:  1990 Oct-Dec

Review 3.  [The renin-angiotensin system in diabetic patients].

Authors:  J Mann; E Ritz
Journal:  Klin Wochenschr       Date:  1988-09-15

4.  Renal kallikrein in diabetic patients with hypertension accompanied by nephropathy.

Authors:  T Baba; S Murabayashi; T Ishizaki; Y Ido; K Aoyagi; K Takebe
Journal:  Diabetologia       Date:  1986-03       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.